Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

Key Takeaways Bristol Myers will acquire Orbital Therapeutics for $1.5 billion.The deal adds OTX-201, an in vivo CAR T-cell therapy for autoimmune diseases.Orbital's RNA platform strengthens BMY's programmable RNA therapy pipeline.Bristol Myers (BMY) recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash.The acquisition will add OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with a potenti ...